 Oramed Pharmaceuticals Inc. Nasdaq: ORMP TASE: ORMP a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801 in type 2 diabetes patients with non-alcoholic steatohepatitis NASH, has shown ORMD-0801 to be safe and well tolerated thus far, with an encouraging lowering of fatty liver content, as seen by MRI- derived proton density fat fraction MRI-PDFF. 